Sorafen 200 mg (Tablet)
Unit Price: ৳ 300.00 (5 x 6: ৳ 9,000.00)
Strip Price: ৳ 1,800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sorafenib tosylate |
| Company | Techno drugs ltd |
Indications
- Hepatocellular Carcinoma
- Renal Cell Carcinoma
Pharmacology
- Kinase inhibitor
- Tumor cell proliferation inhibition
- Inhibition of multiple intracellular and cell surface kinases
Dosage & Administration
- Recommended daily dose of 400 mg tablets
- Twice daily intake without food
- Treatment continuation until clinical benefit or unacceptable toxicity occurs
- Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction
Interaction
- Contraindicated in combination with carboplatin and paclitaxel for squamous cell lung cancer
- Systemic exposure to UGT1A1 and UGT1A9 substrates may increase
- Concomitant use with Docetaxel, Doxorubicin, Fluorouracil, CYP2B6, CYP2C8 substrates, CYP3A4 inducers, CYP3A4 inhibitors, P-glycoprotein substrates should be carefully monitored
Contraindications
- Severe hypersensitivity to Sorafenib
- Contraindicated in combination with carboplatin and paclitaxel for squamous cell lung cancer
Side Effects
- Cardiac ischemia
- Infarction
- Hemorrhage
- Hypertension
- Hand-foot skin reaction
- Rash
- Gastrointestinal perforation
- Wound healing complications
Pregnancy & Lactation
- May cause fetal harm when administered to a pregnant woman
- Women of childbearing potential should avoid becoming pregnant while on Sorafenib
Precautions & Warnings
- Temporary or permanent discontinuation consideration for cardiac ischemia and/or infarction
- Increased risk of bleeding
- Risk of hypertension
- Dermatologic toxicities
- Gastrointestinal perforation
- Warfarin co-administration monitoring for changes in prothrombin time and INR
- Wound healing complications evaluation before resuming therapy
- Interactions with UGT1A1 Substrates, Docetaxel, Doxorubicin
- Hepatic impairment effects on plasma concentrations
- Neomycin co-administration decrease in Sorafen exposure
Use in Special Populations
- Safety and effectiveness not studied in pediatric patients
- No differences in safety or efficacy between older and younger patients
- No dose adjustment required for renal impairment
- Systemic exposure and safety data comparable in HCC patients with mild and moderate hepatic impairment
- Not studied in patients with severe hepatic impairment
Overdose Effects
- No specific treatment for Sorafen overdose
- Adverse reactions observed at highest clinically studied dose of 800 mg twice daily primarily included diarrhea and dermatologic effects
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store at room temperature below 30°C
- Do not remove desiccant
- Dispense in original bottle